CEL-SCI Corporation

CEL-SCI Corporation is a Phase 3 cancer immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. The company is conducting a Phase 3 trial of Multikine (leukocyte interleukin injection) for the treatment of head-and-neck cancer in 17 countries. CEL-SCI is also developing treatments for HIV/HPV coinfected patients with anal warts in collaboration with the U.S. Navy at the San Diego Naval Medical Center through a cooperative research and development agreement. The company operates its own 75,000 sq ft manufacturing facility near Baltimore, MD.